A Multifaceted Model Exploring the Role of Mucus and Shear

Stress in Intestine

Ibrahim Erbay

Understanding Biology Through COMSOL

COMSOL Conference, Florence, 2024






Ollscoil na Gaillimhe


UNIVERSITY OF GALWAY





Introduction: Intestine in Health and Disease

Intestinal flow




~10¹¹ cells/day

Highly mechanical process

Deformed mucus leads to inflammation

Introduction: Intestine in Health and Disease

Intestinal flow



RESEARCH ARTICLE




Modulation of Gut Barrier Functions in Ulcerative Colitis by Hyaluronic Acid System


Niranjan G. Kotla, Isma Liza Mohd Isa, Swetha Rasala, Secil Demir, Rajbir Singh, Becca V. Baby, Samantha K. Swamy, Peter Dockery, Venkatakrishna R. Jala, Yury Rochev,* and Abhay Pandit*

The active stages of intestinal inflammation and the pathogenesis of ulcerative colitis are associated with superficial mucosal damage and intermittent wounding that leads to epithelial barrier defects and increased permeability. The standard therapeutic interventions for colitis have focused mainly on maintaining the remission levels of the disease. Nonetheless, such treatment strategies (using anti-inflammatory, immunomodulatory agents) do not address colitis' root cause, especially the mucosal damage and dysregulated Intestinal barrier functions. Restoration of barrier functionality by mucosal healing or physical barrier protecting strategies shall be considered as an initial event in the disease suppression and progression. Herein, a biphasic hyaluronan (HA) enema suspension, naïve-HA systems that protect the dysregulated gut epithelium by decreasing the inflammation, permeability, and helping in maintaining the epithelial barrier integrity in the dextran sodium sulfate-induced colitis mice model is reported. Furthermore, HA-based system modulates intestinal epithelial junctional proteins and regulatory signaling pathways, resulting in attenuation of inflammation and mucosal protection. The results suggest that HA-based system can be delivered as an enema to act as a barrier protecting system for managing distal colonic inflammatory diseases, including colitis.


intestinal microbiome imbalance^[3,4] resulting in gut barrier dysfunction.[5,6] The active stages of intestinal inflammation (in Crohn's and colitis) are linked to decreased transepithelial resistance and increased permeability.^[7-9] The elevated levels of reactive oxygen species (ROS) and metalloproteinases cause tissue degradation and necrosis induction.[10,11] Moreover, the inflammatory mediator elements are critical causative factors to mucosal inflammation and enhance overall permeability at the gut wall's ulcerative sites.[12-14] Additionally, patients with IBD have decreased levels of tight junctional proteins (claudins, occludins) and junctional adhesion molecules (cadherins, catenins), leading to increased intestinal permeability resulting in systemic inflammation extraintestinal manifestations.^[7,8]


The standard therapeutic interventions for IBD include anti-inflammatory, immunosuppressants, and biological medications, which have focused mainly






Human Colon Histology






Human fecal and mucosal rheology





Rheological properties

Woolley et al., 2013


Srinivasan et al., 2022








Boundary Conditions and Domains




Mucus Increases Flow Velocity




6/10

Mucus reduces shear stress applied on the epithelium



7/10

Mucus reduces shear stress applied on the epithelium



Lower shear magnitude on epithelium in mucus models

Increased fecal mass output in mucus models

Why does this matter?

• Shear stress is known to change cell behaviour in intestine (e.g. division, differentiation, death, mucus secretion and migration)

- We hypothesize that mucus modulates the shear stress transferred to the epithelium and its absence may cause crypt damage via increased mechanical input
- This model could be used for optimizing understanding intestinal biology and drug delivery applications (e.g. nanoparticles)

Acknowledgements

Dr Yury Rochev

University of Birmingham Dr Alessio Alexiadis

All CURAM and lifeTIME CDT members

Thanks for the attention! Any questions?

Poster #09



y

@CDTLifETIME

i.erbay1@universityofgalway.ie

in CDT LIFETIME

in iherbay



CDT LIFETIME

This work was supported by Science Foundation Ireland 18/EPSRC-CDT/3583 and the Engineering and Physical Sciences Research Council EP/S02347X/1. This work has emanated from research supported in part by a grant from Science Foundation Ireland (SFI) and the European Regional Development Fund (ERDF) under grant number 13/RC/2073 P2.



further information **lifetime-ctd.org**